Journal
CLINICAL INFECTIOUS DISEASES
Volume 41, Issue 4, Pages 521-526Publisher
OXFORD UNIV PRESS INC
DOI: 10.1086/432060
Keywords
-
Categories
Funding
- NCI NIH HHS [CA18029] Funding Source: Medline
- NIAID NIH HHS [R01 AI 051468, U01 AI054736] Funding Source: Medline
- PHS HHS [PA18029] Funding Source: Medline
Ask authors/readers for more resources
The epidemiology of invasive fungal infection is evolving. Yeasts other than Candida albicans and molds other than Aspergillus fumigatus have emerged as significant causes of invasive mycoses in severely immunocompromised patients. Although, in some instances, these changes may be related to medical interventions, such as the use of antifungal agents in prophylaxis, in the majority of cases, they seem to be a consequence of changes in the host, such as more-severe immunosuppression or different types of immunosuppression impacting both risk periods and the infections that occur. These factors have altered the epidemiology of infection in organ transplant recipients, premature newborns, and critically ill patients. This review discusses the epidemiology of some fungal infections that have emerged in the past few years, with an emphasis on the potential factors associated with their emergence and on practical implications of these epidemiological changes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available